Please provide your email address to receive an email when new articles are posted on . The study treatment, PT027, is a potential first-in class inhaled, fixed-dose combination rescue medication ...

Credit: AstraZeneca. Airsupra combines albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. Airsupra ® (albuterol/budesonide) is now available for the as-needed ...

Young woman using asthma inhaler at home. The NDA submission is supported by data from the phase 3 MANDALA trial, which included 3132 patients with moderate to severe asthma. The Food and Drug ...

The FDA approved a pressured, metered-dose inhaler containing albuterol and budesonide (Airsupra) for treating adults with asthma, drugmaker AstraZeneca announced. The combination, formerly known as ...

Please provide your email address to receive an email when new articles are posted on . The American College of Allergy, Asthma & Immunology (ACAAI) and American Academy of Allergy, Asthma & ...

As asthma symptoms worsen, patients typically rely on short-acting β 2-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma ...

Two drugs are better than one when it comes to stopping asthma attacks in progress, a new clinical trial has found. The study, of more than 3,100 asthma patients, found that a two-drug "rescue" ...

LAKE FOREST, Ill. -- An ongoing shortage of a medicine commonly used to treat people with breathing problems is expected to get worse after a major supplier to US hospitals shut down last week, CNN ...